ARTL NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Artelo Biosciences Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.77 USD
-24.5% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -77.6% below the Trend Line and sits at 0.2% of its 52-week range. The latest completed week returned -24.5%, after a -30.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 10d.

Setup score 13 out of 100
Latest Close 0.77 USD 31 Jul 2026
1W Return -24.5% latest completed week
4W Return -30.6% short-term follow-through
12W Return -69.7% quarterly tape
Trend Breadth 7.7% 4 of 52 weeks active
Volume Ratio 0.2x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -24.5% Latest completed week; four-week move -30.6%. Indicator stack 4/38 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 39.10% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 56/100 53 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -77.6% below the Trend Line and sits at 0.2% of its 52-week range. The latest completed week returned -24.5%, after a -30.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.2x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0012-week average 0.07

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.00Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -30.6% over four weeks, -69.7% over 12 weeks, and -97.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-24.5%
4W-30.6%
12W-69.7%
26W-85.0%
52W-97.5%
Active trend streak0 weeks
Active weeks in one year4
Trend breadth7.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.67Latest activity-pressure read.
Pressure change-4.1%Four-week change in activity pressure.
Leadership-90.93Latest relative-leadership reading.
RS change0.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 55% Model confidence 52%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength73/100Blend of value, momentum, and quality. Underlying universe rank 28; rank 1 is best.
Value61/100Relative valuation strength. Underlying universe rank 40; rank 1 is best.
Quality59/100Profitability and accounting quality. Underlying universe rank 42; rank 1 is best.
Momentum61/100Medium-term price momentum. Underlying universe rank 40; rank 1 is best.
Growth61/100Revenue and earnings growth. Underlying universe rank 40; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-228.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 53 relevant articles.

14 positive · 35 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-97.6%Distance below the 52-week high.
13-week volatility14.4%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher6 of 2620 weeks finished lower.
Best week+112.0%Week of 20 Mar.
Worst week-35.3%Week of 22 May.
Latest week-24.5%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains0
Flat weeks0
Modest losses4
Sharp losses16
Recent vol14.4%13-week weekly-return volatility.
Base vol22.6%52-week weekly-return volatility.
Up/down split15/37Count of positive and negative weeks in the 52-week window.
Average skew18.7% / -14.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape15/100

Trend, activity pressure, participation, and risk combine to a 15/100 tape read.

 Indicator analysis21/100

Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.

Activity pressure 0.00; No reversal markers Next-Week ExpectancyNegative 39.10%

Next-week expectancy is negative with a 39.10% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors63/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment56/100

Weighted news tone is neutral across 53 relevant articles.

Price to earnings forward of Artelo Biosciences, Inc. – NASDAQ:ARTL Insiders6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.77 USD-24.5%3.43 USD18.54 USD-0.67-90.93981.7KOff
24 Jul 20261.02 USD-11.3%3.54 USD18.77 USD-0.75-88.86545.5KOff
17 Jul 20261.15 USD6.5%3.65 USD18.99 USD-0.78-88.791.7MOff
10 Jul 20261.08 USD-2.7%3.77 USD19.20 USD-0.73-90.85878.0KOff
3 Jul 20261.11 USD-0.9%3.93 USD19.42 USD-0.65-91.681.9MOff
26 Jun 20261.12 USD-11.1%4.07 USD19.65 USD-0.55-91.97873.2KOff
19 Jun 20261.26 USD-7.4%4.21 USD19.87 USD-0.41-91.67618.6KOff
12 Jun 20261.36 USD-1.4%4.34 USD20.09 USD-0.33-91.031.7MOff
5 Jun 20261.38 USD-1.4%4.48 USD20.31 USD-0.23-91.011.9MOff
29 May 20261.40 USD17.6%4.65 USD20.54 USD-0.10-91.5629.9MOff
22 May 20261.19 USD-35.3%4.91 USD20.75 USD0.02-92.8320.3MOff
15 May 20261.84 USD-27.6%5.21 USD20.93 USD0.25-89.078.9MOff
8 May 20262.54 USD-25.1%5.57 USD21.13 USD0.43-85.31577.8KOff
1 May 20263.39 USD-16.0%5.93 USD21.30 USD0.65-79.861.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.